Oceania · Markets & Finance · Stockhead

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Published by Stockhead · Australia 1 h ago

CSL will pay an upfront US$355 million ($515m) to co-develop an external drug candidate aimed at treating rare kidney and ... Read More The post Health Check: CSL places…

Read the full article on Stockhead Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)

Also worth reading

Business News (WA)

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Share

Also worth reading

Orbital inks second Indian drone propulsion deal

Has AI Reset the Cycle?

The Trust Trap: why tighter control can hurt a growing business

Property downturn worsens with less than 50pc of auctions leading to a sale

Pavlova hits the Big Apple as Gelato Messina makes New York debut

Fulton Hogan revenues and profits rebound after 2025 downturn